India Glycols Plans To Launch One New API Each Year And Expand Dietary Fibre

Market snapshot: India Glycols has outlined a structured expansion blueprint for its newly demerged biopharma business, Ennature Bio Pharma Limited. The strategy focuses on launching one new Active Pharmaceutical Ingredient (API) annually while moving aggressively into the high-margin dietary fibre segment. Additionally, the company is intensifying operations to defend and grow its global footprint in Thiocolchicoside and specialized Nicotine derivatives.

Data Snapshot

• The demerged biopharma business, Ennature Bio Pharma, targets an EBITDA of ₹130 crore to ₹150 crore over the next four to five years.
• Under the demerger scheme, India Glycols shareholders receive one equity share of Ennature Bio Pharma for every three shares held, and one share of IGL Spirits for every one share held.
• The dietary fibre expansion will leverage a specialized Guar Gum sub-segment that is projected by CARE Ratings to contribute ₹65 crore to ₹70 crore in revenue at high operating margins of 25% to 30%.

What's Changed

• The biopharma and nutraceutical businesses, which formerly operated under the Ennature Biopharma division of India Glycols, have been spun off into a separate, independently managed listed entity named Ennature Bio Pharma Limited, effective September 1, 2026.
• To counter margin erosion from commodity players in pure nicotine, the business is shifting its focus to patented high-purity derivatives and clinical-backed branded products.

Key Takeaways

• Pipeline-driven diversification will be led by launching one new plant-based API every year.
• Entry into the dietary fibre market is anchored by the integration of the high-margin Guar Gum business, yielding strong projected cash flows.
• Consolidating market share in Thiocolchicoside (skeletal muscle relaxant) and ultra-pure Nicotine derivatives targets recovery in operating profitability.

SAHI Perspective

The three-way corporate demerger of India Glycols is a tactical value-unlocking catalyst. Historically, the high-margin potential of the biopharma division was obscured by the capital expenditure requirements of the bulk chemicals segment. By establishing Ennature Bio Pharma as an independent pure-play, management is addressing the conglomerate discount. Transitioning from bulk commodity extraction to high-barrier clinical-backed derivatives and structured annual API launches is a robust strategic step to insulate margins from overcapacity pricing pressures.

Market Implications

The separation of the chemicals, spirits, and biopharma segments allows for clean valuation structures. Institutional investors seeking exposure to the global nutraceutical and active pharmaceutical ingredient trends can now directly target Ennature Bio Pharma. Supported by recent USFDA clearance with zero observations for dietary supplements at the Dehradun facility, the biopharma business is positioned to command premium valuation multiples.

Trading Signals

Market Bias: Bullish

Value unlocking from the three-way corporate split, effective September 1, 2026, is a key medium-term positive. Isolating the biopharma segment, which targets ₹130 crore to ₹150 crore in EBITDA in the next 4-5 years, underpins a constructive bias on the demerged entities.

Overweight: Pharma, Specialty Chemicals, Nutraceuticals

Trigger Factors:

• Listing of the demerged Ennature Bio Pharma and IGL Spirits shares on the stock exchanges.
• Successful commercial launch of the first pipeline plant-based API under the yearly program.
• Margin validation in subsequent quarterly earnings post-demerger.

Time Horizon: Medium-term (3-12 months)

Industry Context

The global pharmaceutical and nutraceutical sectors are experiencing an elevated shift toward green chemistries and plant-based active ingredients. While basic extraction has become highly commoditized with severe pricing pressure from new entrants, value-added formulations and strict regulatory certifications (such as EU-GMP and USFDA) remain high-barrier. Establishing a pipeline of yearly API releases and integrating specialized dietary fibers enables players to secure sticky export contracts.

Key Risks to Watch

• Potential regulatory delays in securing CEP from the EDQM or international DMF clearances for the annual API launches.
• Extended pricing pressure in the global nicotine market from emerging domestic and Chinese suppliers.
• Operational execution risks during the transitional phase of the corporate split.

Recent Developments

India Glycols announced September 1, 2026, as the effective demerger date, with September 2, 2026, set as the record date for share allotments. An analyst and investor physical meeting was scheduled in Mumbai on September 2, 2026, to discuss the post-split operational roadmap. The corporate demerger was approved by the National Company Law Tribunal (NCLT) on July 17, 2026.

Closing Insight

The strategic transition from a chemical conglomerate to focused pure-plays sets a strong foundation for India Glycols' next phase of growth. While the core chemicals business maintains volume stability, the newly independent biopharma entity offers high-margin innovation potential, backed by specialized APIs, dietary fibres, and a robust regulatory-ready asset base.

High Performance Trading with SAHI.